Loading organizations...
Based in San Diego, California, Genalyte is a life sciences enterprise that develops multiplexing diagnostic technology to enable rapid, blood-based testing directly within physician offices. The organization commercializes the Maverick and Merlin platforms, which are engineered to deliver on-demand, on-site laboratory results for autoimmune antigen panels and immunogenicity testing in under 30 minutes. By targeting both clinical diagnostics and biopharmaceutical drug development, these proprietary systems provide medical professionals with immediate quantitative data. This approach is designed to inform routine patient care and accelerate complex clinical trials. Genalyte has financed its hardware and assay development operations through multiple venture capital transactions, highlighted by a $44 million Series C funding round backed by institutional investors including Khosla Ventures, Redmile Group, BioMed Realty Ventures, and Claremont Creek Ventures. The private diagnostic company was founded in 2007 by Cary Gunn.
Genalyte has raised $47.8M across 2 funding rounds.
Genalyte has raised $47.8M in total across 2 funding rounds.
Genalyte has raised $47.8M across 2 funding rounds. Most recently, it raised $36.0M Other Equity in November 2016.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Nov 21, 2016 | $36M Venture Round | Vinod Khosla, Redmile Group | — | Announced |
| Mar 30, 2012 | $11.8M Series B | — | Claremont Creek Ventures, Redmile Group | Announced |
Genalyte has raised $47.8M in total across 2 funding rounds.
Genalyte's investors include Vinod Khosla, Redmile Group, Claremont Creek Ventures.
